2023-04-24

Parkinson’s Awareness Month: Updates in Parkinson’s Disease Diagnosis and Treatment

Parkinson’s disease is the second most common progressive neurodegenerative disorder worldwide. In Canada alone, more than 100,000 people have Parkinson’s disease (approximately 1 in 500 people). Furthermore, the number of Canadians living with Parkinsonism is expected to double by 2031. 

In light of these alarming stats, it’s crucial to spread awareness regarding this devastating disease. Hence, April has been designated as Parkinson’s Awareness Month. To honour and promote this spirit of Parkinson’s awareness, here’s some of the latest information on Parkinson’s disease diagnosis and treatment to broaden your horizons.

Updates in Parkinson’s Disease Diagnosis

Parkinson’s disease is mainly diagnosed clinically through medical history and motor or movement-related symptoms like tremors, stiffness, and balance issues. However, this disease can also present with non-motor symptoms like: 

  • fatigue
  • sleep issues
  • respiratory problems
  • speech or swallowing difficulties
  • cognitive changes 
  • diminished sensory function
  • digestive issues
  • decreased bone health
  • urinary incontinence
  • mental illnesses like behaviour (hallucinations, delusions, dementia) and mood disorders 

Parkinson’s research remains focused on identifying definitive biomarkers to accurately measure disease activity, progression, and treatment effectiveness. At the molecular level, abnormal clusters of misfolded alpha-synuclein proteins are characteristic of Parkinson’s disease. Thus, spinal taps and skin (including nerve) biopsies to detect this protein may come in handy while trying to make a conclusive Parkinson’s diagnosis. Other diagnostic modalities include the use of positron emission tomography (PET) scans to identify alpha-synuclein accumulation in the brain. Alpha-synuclein radiotracers are still being developed.

Since a lack of dopamine neurotransmitter stimulation is mainly responsible for the motor symptoms of Parkinson’s disease, dopamine transporters (daT) have become one of the most popular biomarkers to be studied. These can be detected through brain imaging technology like daTscan, which uses a radioactive chemical to identify areas of the brain where dopamine-producing neurons have been lost. 

Biomarkers assessing the function of the autonomic nervous system are also being researched since non-motor symptoms can precede motor symptoms in many Parkinson’s disease cases.  

Updates in Parkinson’s Disease Therapy

While there’s still no definitive cure for Parkinson’s, levodopa has been the mainstay of treatmenttreatment since the 1960s. The efficacy of levodopa therapy remains undisputed, but the use of novel delivery systems like biodegradable polymer polylactic-glycolic acid (PLGA), and liposomes are now being explored to enhance drug delivery to the brain. 

Patients with possible diagnosis of Parkinson disease may also benefit from a trial of dopamine replacement therapy to help with diagnosis.

Furthermore, scientists are looking to repurpose drugs that suppress the immune system (azathioprine), affect other bodily functions (e.g., iron chelators like deferiprone and calcium channel blockers like isradipine), or are usually used for other indications (e.g., cough medications like ambroxol) to mitigate Parkinson’s disease symptoms. 

Some of the most popular alternative treatment modalities being researched include:

  1. immunotherapies via monoclonal antibodies
  2. stem cell therapy
  3. gene therapy
  4. deep brain stimulation
  5. regenerative therapies

Meanwhile, neuroprotective and symptomatic treatment remains the current focus of Parkinson’s disease management. This can involve supportive treatments like physical therapy for motor symptoms, and speech therapy for non-motor symptoms like speech impediments.

Thus, although disease cases are on the rise, Parkinson’s research is trying its best to catch up to a cure at the earliest.

Keep Learning With MDBriefCase

If you enjoyed this article and are looking for similar information on a wide range of topics, be sure to check out the MDBriefCase for the latest medical information. We also provide free continuing medical education and professional development courses, courses for specialists, and more.

Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Lab website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.

Audience and Appropriate Topics

The  Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.

Parameters

Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words. 

Review

MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement